Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Plus: Covid mission creep; Oxfam on colonialism; blaming Boomers; life before plastic wrappers; and the exploits of the ...

President Trump’s health secretary nominee, Robert F. Kennedy Jr., on Wednesday said vaccines are a critical component of ...

In November 2023 Colombia imposed a tax on highly processed foods and drinks. Authorities in Brazil, Canada and Peru have ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

As a reminder, charts ... rates are having. U.S. whiskey sales volume declined for a second consecutive year in 2024. It had previously risen every year between 2002 and 2022. The Wall Street Journal ...

It may also, as a result, impact how obesity drugs are prescribed. Wegovy and Zepbound are approved in the US for anyone with a BMI of 30 or more. The threshold is 27 for individuals with a ...

The United States will leave the World Health Organization, President Donald Trump said on Monday, saying the global health agency had mishandled the COVID-19 pandemic and other international health ...